EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 24-Dec-2025 14:11 ET (24-Dec-2025 19:11 GMT/UTC)

3-Nov-2025

New antibody therapy reawakens immune system to fight pancreatic cancer

Northwestern University
Peer-Reviewed Publication

Pancreatic cancer is notoriously hard to treat and often resists the most advanced immunotherapies. Northwestern Medicine scientists have uncovered a novel explanation for that resistance: Pancreatic tumors use a sugar-based disguise to hide from the immune system. The scientists also created an antibody therapy that blocks the sugar-mediated “don’t-attack” signal.

Journal: Cancer Research

3-Nov-2025

Researchers discover a safe new target against Acute Myeloid Leukaemia

Josep Carreras Leukaemia Research Institute
Peer-Reviewed Publication

Targeting a specialized group of histones is safe and opens new therapeutic opportunities for treating blood cancers. This is the main finding of the latest research by Dr Marcus Buschbeck and Dr René Winkler, researchers at the Josep Carreras Leukaemia Research Institute. Experimental results confirm that the removal of any of the three proteins of the macroH2A family of histones, linked to Acute Myeloid Leukaemia, is well tolerated in mice and has no major effect on their health.

Journal: Science Advances

3-Nov-2025

New switch for programmed cell death identified

Technical University of Munich (TUM)
Peer-Reviewed Publication

- Science learns from nature's methods

- Potential benefits for future therapies against cancer and Alzheimer's disease

- Joint research by TUM and Helmholtz Munich

In the fight against disease, programmed cell death – also known as apoptosis – is a key protective function of the body. It breaks down cells that are damaged or have undergone dangerous changes. However, cancer cells often manage to override this mechanism. A research team at the Technical University of Munich (TUM) has now succeeded in identifying a new molecular switch in this process and elucidating how it works.

Journal: Nature Communications

2-Nov-2025

From blood to solid tumors: A new way to power up CAR T cell therapy

Monash University
Peer-Reviewed Publication

Solid tumours, which account for around 90 per cent of all adult cancers, remain a major challenge for CAR T cells to infiltrate.Researchers in Australia have used CRISPR-based gene editing or a PTPN2 inhibitor to enhance the function of human CAR T cells engineered to recognize an antigen expressed on many solid tumours.

Journal: Science Translational Medicine

31-Oct-2025

Student's unexpected rise as a researcher leads to critical new insights into HPV

University of Delaware
Peer-Reviewed Publication

Once a lab novice, UD senior Sean Fletcher uncovered key molecular insights into HPV. Using computational biology, he identified conserved regions in the viral E2 protein vital to replication and cancer risk, and found mutations that may disrupt E2 function and increase cancer potential.

Journal: Virology Journal

31-Oct-2025

Immunotherapy resistance in kidney cancer driven by myeloid cell signaling

Dana-Farber Cancer Institute
Peer-Reviewed Publication

Biomarkers used in other cancers to predict a response to immune checkpoint inhibitors do not work for renal cell carcinoma. The results of this Dana-Farber Cancer Institute study could help investigators discover biomarkers to help identify which patients will be likely respond to immunotherapy and which might benefit from a different treatment strategy.

Journal: Immunity

31-Oct-2025

MSK Research Highlights, October 31, 2025

Memorial Sloan Kettering Cancer Center
Peer-Reviewed Publication

New research from Memorial Sloan Kettering Cancer Center (MSK) uncovers unique genetic signatures in cancer patients of non-European ancestry; identifies social adversity as a potential risk factor for higher rates of triple-negative breast cancer among Black women; shows a web-based system could help head-and-neck cancer survivors report their concerns; and finds adding immunotherapy can boost the effectiveness for hard-to-treat follicular lymphomas.

31-Oct-2025

DNA copy-number changes help melanoma develop resistance to immunotherapy, UCLA study finds

University of California - Los Angeles Health Sciences
Peer-Reviewed Publication

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators reveals how melanoma, the deadliest form of skin cancer, evolves to resist immunotherapy and identifies a potential strategy to prevent or reverse that resistance.

Journal: Immunity
Funder: National Institutes of Health, V Foundation for Cancer Research, Melanoma Research Alliance, Melanoma Research Foundation

31-Oct-2025

Researchers at MIT develop new nanoparticles that stimulate the immune system to attack ovarian tumors

Massachusetts Institute of Technology
Peer-Reviewed Publication

MIT researchers designed nanoparticles that can deliver an immune-stimulating molecule called IL-12 directly to ovarian tumors. When given to mice along with checkpoint inhibitors, the treatment eliminated metastatic tumors more than 80 percent of the time.

Journal: Nature Materials
Funder: NIH/National Institutes of Health, Marble Center for Nanomedicine, Deshpande Center for Technological Innovation, Ragon Institute of MGH, MIT, and Harvard, Koch Institute Support (core) Grant from the National Cancer Institute

31-Oct-2025

RNA modification m⁶A emerges as key player in cancer development and therapy

Sichuan International Medical Exchange and Promotion Association
Peer-Reviewed Publication

In a review published in Molecular Biomedicine, a team of Chinese scientists summarizes the pivotal role of N⁶-methyladenosine (m⁶A)—the most abundant chemical modification in eukaryotic mRNA—in cancer biology. The authors describe how m⁶A regulators (writers, erasers, and readers) influence tumor progression, metastasis, treatment resistance, and the tumor microenvironment. They also discuss emerging therapeutic strategies, including small-molecule inhibitors, RNA-based editing technologies, and combination therapies, highlighting m⁶A's potential as a diagnostic and prognostic biomarker and a target for precision oncology.

Journal: Molecular Biomedicine